BPC-157 vs TB-500: Research Comparison
BPC-157 and TB-500 are the two most-compared healing-and-repair research peptides, but they sit in different mechanistic lanes: BPC-157 in cytoprotective, angiogenic, VEGF-linked signalling, and TB-500 in actin-binding, cell-migration biology. This is the choose-between read — for the case for running them together, see the dedicated blend article.
Update History ▾
October 7, 2026: Added the July 2026 advisory committee votes, FDA's Category 2 listing and the WADA 2027 Prohibited List entries for both compounds; restated the RGN-259 status as of October 2026.
BPC-157 and TB-500 are both research-use-only healing-and-repair peptides, but they are not interchangeable. BPC-157 is a 15-amino-acid synthetic pentadecapeptide (CAS 137525-51-0, MW 1419.55 g/mol) derived from a sequence in human gastric juice; its preclinical signal centres on nitric-oxide-system modulation, VEGF/eNOS-driven angiogenesis, and FAK-paxillin growth-factor activity.[1] TB-500 is defined by FDA and the anti-doping literature as Ac-LKKTETQ, a seven-residue fragment of Thymosin Beta-4 (Tβ4 reference CAS 77591-33-4), though products sold under the name vary.[7][8] The G-actin sequestration, cell-migration and angiogenesis biology it is studied for is documented for full-length Tβ4;[2] a 2024 analysis notes that the effects of TB-500 itself have not been documented.[9] Both are preclinical-dominant. BPC-157's human record is five small studies (two placebo-controlled enema studies from 2002–2005, reported only as conference abstracts, and three uncontrolled pilot reports by one Florida physician), and no controlled trial has shown efficacy.[3][6] The clearest human Thymosin Beta-4 record is the RegeneRx RGN-259 ARISE ophthalmic programme, which tests full-length Tβ4 rather than the marketed TB-500 fragment.[2]
Fast Comparison: BPC-157 vs TB-500
| Point of comparison | BPC-157 | TB-500 (Tβ4 fragment) |
|---|---|---|
| Peptide class | 15-amino-acid synthetic pentadecapeptide derived from a sequence in human gastric juice (CAS 137525-51-0, MW 1419.55 g/mol). | Defined by FDA and the anti-doping literature as Ac-LKKTETQ, a seven-residue synthetic fragment (889 g/mol) of Thymosin Beta-4, a 43-amino-acid actin-binding protein (Tβ4 reference CAS 77591-33-4, MW 4,963.4 g/mol); products sold under the name vary.[7] |
| Primary mechanism | Cytoprotective and angiogenic signalling: nitric-oxide-system modulation, VEGF/eNOS-driven angiogenesis, and FAK-paxillin growth-factor activity. | Actin-cytoskeleton lane: 1:1 G-actin sequestration, cell migration and angiogenesis are documented for full-length Tβ4, while the effects of TB-500 itself have not been documented (AcSDKP signalling also belongs to full-length Tβ4, not the TB-500 fragment).[9] |
| Tissue focus | Tendon, ligament, gut-mucosal, and vascular repair models. | Cardiac infarct repair, corneal wound, dermal wound, and tendon/ligament repair models. |
| Research evidence base | Preclinical-dominant; the human record is five small studies: two placebo-controlled enema studies (2002–2005, conference abstracts only) and three uncontrolled pilot reports by one Florida physician (2021–2025). No controlled trial has shown efficacy.[6] | Preclinical-dominant; clearest human record is the RegeneRx RGN-259 ARISE Phase 3 ophthalmic programme for full-length Tβ4 (mixed endpoints, no FDA approval as of October 2026). |
| Regulatory status (October 2026) | Not approved. FDA advisers voted 8-6-1 in July 2026 to recommend it for the 503A bulks list (ulcerative colitis; non-binding, no final FDA action). Listed by FDA as nominated but withdrawn from Category 2. Named under S0 on the WADA 2027 List.[10][11][12] | Not approved. FDA advisers voted 8-6-1 in July 2026 to recommend it for the 503A bulks list (wound healing; non-binding, no final FDA action). Listed by FDA as nominated but withdrawn from Category 2. Named under S2 on the WADA 2027 List.[10][11][12] |
| Format sold | BPC-157 10mg research vial; >99% HPLC purity; lyophilized, 2-8°C cold-chain. | TB-500 10mg research vial; >99% HPLC purity; lyophilized, 2-8°C cold-chain. |
What Is BPC-157?
BPC-157 (Body Protection Compound 157) is a 15-amino-acid synthetic pentadecapeptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, CAS 137525-51-0, MW 1419.55 g/mol) derived from a stable fragment of a protein originally isolated from human gastric juice.[1]
Its preclinical signal centres on tissue-repair models involving the nitric-oxide system, VEGF/eNOS angiogenic signalling, and FAK-paxillin growth-factor activity. The recurring rodent phenotype is improved perfusion and accelerated stromal repair across tendon, ligament, gut-mucosal, and vascular injury models.[1] The deeper mechanism walk-through lives in the dedicated BPC-157 healing peptide review.
It is supplied as a 10mg lyophilized research vial at >99% HPLC purity for in-vitro laboratory research. It is not an approved medicine and there is no established human dosage or protocol.
What Is TB-500?
TB-500 is a common name for synthetic peptide material derived from Thymosin Beta-4 (Tβ4), the principal G-actin-sequestering peptide in mammalian cells. Full-length native Tβ4 is a 43-amino-acid acidic peptide (reference CAS 77591-33-4, reference MW 4,963.4 g/mol).[4] FDA and the anti-doping literature define TB-500 as Ac-LKKTETQ (Tβ4 residues 17–23, 889 g/mol), a synthetic N-acetylated heptapeptide that keeps the central actin-binding motif but not the N-terminal AcSDKP sequence (residues 1–4).[7][8] Products sold under the name vary, and some contain or claim full-length Tβ4 (about 4,963 g/mol), so a vial's COA mass is what identifies its contents.[7][8]
The actin biology belongs to full-length Tβ4: Tβ4 binds monomeric G-actin in a 1:1 complex and modulates the G-actin / F-actin equilibrium during cytoskeletal remodelling, which underlies lamellipodial protrusion, fibroblast migration, and keratinocyte sheet movement.[2] TB-500 itself is far less characterised: activity data exist for the unacetylated LKKTETQ peptide, but a 2024 analysis notes that the biological effects of TB-500 have not been documented.[9] A distinct strand of full-length Tβ4 research involves its AcSDKP N-terminal fragment, a separately characterised anti-fibrotic and haematopoietic regulator that the TB-500 fragment does not contain.[5] The full mechanism walk-through lives in the dedicated TB-500 (Thymosin Beta-4 fragment) review.
It is supplied as a 10mg lyophilized research vial at >99% HPLC purity for in-vitro laboratory research.
Mechanism-by-Mechanism Contrast
The cleanest way to separate the two compounds is by the biology they touch. The pathway split is non-overlapping:
- BPC-157 — the vascular and stromal lane. Rodent studies report that BPC-157 modulates the nitric-oxide system, upregulates VEGFR2 and downstream eNOS-mediated angiogenic signalling in endothelial-cell models, and activates focal-adhesion kinase / paxillin phosphorylation in tendon and fibroblast preparations. The phenotype is improved perfusion and accelerated stromal repair.[1]
- TB-500 — the actin-cytoskeleton lane. Native Thymosin Beta-4 binds monomeric G-actin in a 1:1 complex, maintains the cytoplasmic G-actin pool, and modulates the G-actin / F-actin equilibrium during cytoskeletal remodelling. Functionally this is the building block of lamellipodial protrusion, fibroblast migration, and keratinocyte sheet movement — the cell-migration component of wound re-epithelialisation. These are documented properties of full-length Tβ4; the effects of TB-500 itself have not been documented.[9] A distinct strand of full-length Tβ4 research involves its AcSDKP N-terminal fragment, an endogenous regulator of haematopoietic stem-cell cycling and a separately characterised anti-fibrotic peptide; the TB-500 fragment does not contain it.[2][5]
Read side by side, BPC-157 modulates the vascular and growth-factor signal underneath a repair site, while TB-500 is studied for the cytoskeletal-migration signal documented for full-length Tβ4. That is why the two are not substitutes: a research design that needs an angiogenic / nitric-oxide endpoint is a BPC-157 question, and a design that needs an actin-binding or cell-migration endpoint is a TB-500 question.
When Researchers Study Each
BPC-157 belongs in studies asking how a cytoprotective, gastric-protein-derived peptide changes vascular and stromal repair signalling. Relevant endpoints include VEGFR2 / eNOS angiogenic signalling, nitric-oxide-system modulation, FAK-paxillin phosphorylation, and tendon, ligament, gut-mucosal, or vascular injury models. The deeper mechanism and the small human record are covered in the BPC-157 healing peptide review.
TB-500 belongs in studies asking how a Thymosin Beta-4 fragment changes actin-cytoskeleton dynamics and cell migration. Relevant endpoints include G-actin sequestration, lamellipodial protrusion, fibroblast and keratinocyte migration, and endothelial tube formation; AcSDKP signalling is a full-length Tβ4 endpoint, not a TB-500 one. Note the labelling distinction: the marketed TB-500 fragment is not the same regulatory entity as the full-length Tβ4 used in the RegeneRx RGN-259 ophthalmic programme, so full-length Tβ4 mechanism papers do not map 1:1 onto a TB-500 vial.[7] The TB-500 review covers the fragment-vs-full-length distinction and the ARISE ophthalmology status in full.
For product-format details, compare the BPC-157 10mg research vial and the TB-500 10mg research vial; both ship under the same 2-8°C cold-chain handling.
Evidence Base and Limits
Both compounds are preclinical-dominant, and neither has a late-stage human musculoskeletal trial. For BPC-157, the human record is five small studies. Two placebo-controlled enema studies from 2002–2005 were reported only as conference abstracts: a 32-person phase 1 safety study and a 53-person ulcerative-colitis trial.[6] The other three are uncontrolled pilot reports by one Florida physician: a 2021 knee-pain chart review, a 2024 interstitial cystitis pilot in 12 women, and the Lee and Burgess 2025 two-subject IV safety pilot (PMID 40131143).[3] No controlled trial has shown efficacy: FDA's July 2026 briefing found the one randomised trial too thinly reported and exploratory to support effectiveness.[6] The only human data on the combination come from the 2021 review, in which 4 of 16 patients received BPC-157 with thymosin beta-4 (the paper does not say which form).[3]
For Thymosin Beta-4, the clearest human record is the RegeneRx RGN-259 ARISE Phase 3 dry-eye programme — a preservative-free 0.1% Tβ4 eye drop with mixed sign/symptom endpoints and no FDA approval as of October 2026. Two caveats matter: that programme tests full-length Tβ4, not the marketed TB-500 fragment, and a ClinicalTrials.gov search returns no Phase 2 or Phase 3 human musculoskeletal trial for TB-500 or the fragment.[2]
Neither compound is approved. On July 23, 2026 the FDA Pharmacy Compounding Advisory Committee voted 8-6-1 to recommend BPC-157 (for ulcerative colitis) and 8-6-1 to recommend TB-500 (for wound healing) for the 503A bulks list.[10] The votes are non-binding, and the FDA had taken no final action as of October 7, 2026. FDA's Category 2 page (updated April 22, 2026) lists both as nominated but withdrawn.[11] The FDA peptide reclassification tracker follows the process. In sport, the WADA 2027 Prohibited List, in force from January 1, 2027, names BPC-157 under S0 and “Thymosin-β4 and its derivatives e.g. TB-500” under S2.[12]
The honest summary: both are well-characterised at the preclinical level in different lanes, and both have thin-to-absent late-stage human records. Any source presenting either as a finished, validated human therapy is going past the published evidence.
Why They Are Often Studied Together
Because the pathways are non-overlapping, investigators sometimes co-administer the two in animal-model repair work: BPC-157 contributes the vascular and growth-factor signal while TB-500 is chosen for the actin-driven cell-migration signal documented for full-length Tβ4. The rationale is mechanistic complementarity, not published synergy — synergy is a specific pharmacological claim that requires combination data showing the joint effect exceeds the additive sum, and no such combination dataset has been published for BPC-157 + TB-500.[1][2]
Remy supplies a co-formulated BPC-157 + TB-500 5mg + 5mg blend vial for researchers who want a fixed 1:1 mass-ratio format, while the separate BPC-157 and TB-500 vials suit investigators who need each compound on its own. The full combination evidence review — the absence of any human combination trial, the complementary-vs-synergy distinction, and the FDA PCAC compounding backdrop — is in the BPC-157 + TB-500 blend mechanism & synergy article.
Storage & Handling
Both compounds are handled like other short research peptides, and the storage chemistry is the same for either vial:
- Storage of the lyophilisate. 2-8°C protected from light for routine use; -20°C for long-term storage. In warm climates, documented cold-chain handling from arrival to bench-side is important — short ambient excursions during last-mile delivery are the most common stability risk.
These notes describe the research-vial format only. The page provides no human-use dosing, preparation or veterinary instructions and is not a clinical-protocol document. Wider storage questions are covered in the peptide stability and storage guide.
BPC-157 & TB-500 Research-Use Supply & Format
For research use, both compounds belong in the category of healing-and-repair research peptides — each supplied as a 10mg lyophilized research vial at >99% HPLC purity, with cold-chain handling for in-vitro work. The BPC-157 10mg research vial and TB-500 10mg research vial ship under the same 2-8°C cold-chain, with the active lot reference confirmed before dispatch.
Researchers who want a fixed 1:1 co-administration format can use the co-formulated BPC-157 + TB-500 blend vial instead; the combination question itself is reviewed in the blend mechanism & synergy article. Material is supplied strictly for in-vitro laboratory research. It is not framed for human use, not framed for veterinary use, and not framed as a treatment.
Our Research Standards
This article uses peer-reviewed primary literature and reviews, and limits product references to research-use format and verification. Where the human clinical record is thin or absent, we say so directly. No therapeutic, human-use, or veterinary-use claim is made here. Read our editorial policy →
BPC-157 vs TB-500 FAQ
What is the main difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid synthetic pentadecapeptide derived from a sequence in human gastric juice, studied in preclinical models for nitric-oxide-system modulation, VEGF/eNOS-driven angiogenesis, and FAK-paxillin growth-factor signalling. TB-500 is defined by FDA and the anti-doping literature as Ac-LKKTETQ, a seven-residue fragment of Thymosin Beta-4 (Tβ4), though products sold under the name vary. It is studied for the G-actin sequestration and cell-migration biology documented for full-length Tβ4, and a 2024 analysis notes that the effects of TB-500 itself have not been documented; as defined, it does not contain the AcSDKP N-terminal fragment of full-length Tβ4. They sit in different lanes: BPC-157 in vascular and stromal repair signalling, TB-500 in actin-cytoskeleton and cell-migration biology.
Which one has stronger research evidence, BPC-157 or TB-500?
Both are preclinical-dominant. BPC-157's human record is five small studies: two placebo-controlled enema studies from 2002–2005 reported only as conference abstracts (a 32-person phase 1 safety study and a 53-person ulcerative-colitis trial), and three uncontrolled pilot reports by one Florida physician (2021, 2024, 2025). No controlled trial has shown efficacy: FDA's July 2026 briefing found the one randomised trial too thinly reported and exploratory to support effectiveness. TB-500's clearest human record is the RegeneRx RGN-259 ARISE Phase 3 dry-eye programme for full-length Thymosin Beta-4, which had mixed endpoints and no FDA approval as of October 2026 — and that programme tests full-length Tβ4, not the marketed TB-500 fragment. Neither compound has a late-stage human musculoskeletal trial.
Can BPC-157 and TB-500 be used interchangeably in a study?
No. They are studied in different mechanistic lanes. BPC-157 is studied for angiogenic, nitric-oxide, and FAK-paxillin stromal-repair signalling. TB-500 is studied for the G-actin sequestration and cell-migration biology documented for full-length Thymosin Beta-4. A research design built around one does not substitute for the other; they answer different questions.
Why are BPC-157 and TB-500 often studied together?
The rationale is mechanistic complementarity rather than published synergy. BPC-157 contributes the vascular and growth-factor signal, while TB-500 is chosen for the actin-driven cell-migration signal documented for full-length Thymosin Beta-4. The pathways are non-overlapping, which is the published basis for co-administration in animal-model repair work. No peer-reviewed human combination trial exists, so the honest description is complementary co-administration, not synergy. The combination question is reviewed in detail in the BPC-157 + TB-500 blend article.
How are BPC-157 and TB-500 supplied and handled for research use?
Remy Research supplies BPC-157 10mg and TB-500 10mg as separate lyophilized research vials at >99% HPLC purity, plus a co-formulated 5mg + 5mg blend vial, all under 2-8 degrees Celsius cold-chain handling. Both are stored at 2-8 degrees Celsius, protected from light. They are supplied strictly for in-vitro laboratory research, and are not framed for human use, veterinary use, or therapeutic application.
Sources
- Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. doi: 10.2174/1570159X13666160502153022 · PMID: 27138887. See also Hsieh MJ et al., J Mol Med 2017;95(3):323-333 on the VEGFR2 pathway, PMID: 27847966. Mechanism depth in the dedicated BPC-157 review. ↵
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. doi: 10.1517/14712598.2012.634793 · PMID: 22074294. Bock-Marquette I et al., Nature 2004;432(7016):466-472 on cardiac repair, PMID: 15565145. RegeneRx RGN-259 ARISE Phase 3 dry-eye programme context. Mechanism depth in the dedicated TB-500 review. ↵
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PMID: 40131143. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. PMID: 39325560. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMC: PMC12446177. ↵
- National Center for Biotechnology Information. PubChem Compound Summary for Thymosin Beta-4 (Tβ4). pubchem.ncbi.nlm.nih.gov/compound/Thymosin-beta-4 ↵
- Cavasin MA. Therapeutic potential of thymosin-β4 and its derivative N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) in cardiac healing after infarction. Am J Cardiovasc Drugs. 2006;6(5):305–311. PMID: 17083265 ↵
- U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026: BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate). Appendix 1: previous human experience with BPC-157. fda.gov/media/193343/download ↵
- U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026: TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate). fda.gov/media/193349/download ↵
- Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PMID: 23084823. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. PMID: 22962027. Delcourt V, Garcia P, Chabot B, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023;15(4):458-464. PMID: 36482504. Delcourt V, Garcia P, Chabot B, et al. Equine Doping Controls of Thymosin β4: A Population Study and Strategy for Misuse Detection. Drug Test Anal. 2025;17(7):1071-1077. PMID: 39314109. ↵
- Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033. doi: 10.1016/j.jchromb.2024.124033 · PMID: 38382158. ↵
- U.S. Food and Drug Administration. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. fda.gov. Vote tallies: AJMC. ↵
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2). Updated April 22, 2026. fda.gov ↵
- World Anti-Doping Agency. 2027 Prohibited List. Published September 21, 2026; in force January 1, 2027. wada-ama.org ↵
For catalog details, see the BPC-157 10mg research vial, the TB-500 10mg research vial, and the BPC-157 + TB-500 blend vial. For the wider range, browse the non-retatrutide research peptide Dubai catalog with line-standard HPLC purity. For the combination question, continue to the BPC-157 + TB-500 blend mechanism & synergy article.